Expert Ratings for Tarsus Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Tarsus Pharmaceuticals (NASDAQ:TARS) has received predominantly bullish ratings from analysts in the last quarter, with 6 bullish and 1 somewhat bullish ratings. The company's average 12-month price target has increased by 2.93% from $44.00 to $45.29.
September 11, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tarsus Pharmaceuticals has received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up.
Analyst ratings often influence investor sentiment. The predominantly bullish ratings for Tarsus Pharmaceuticals indicate a positive outlook for the company, which could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100